Global digital health company Ada Health has launched an online platform for Covid-19 developed with support from Pfizer.
The COVID-19 Care Journey platform will enable users to determine if they fit the existing standards for progression to severe disease and get in touch with a medical professional to examine their symptoms and available treatment options.
The online platform offers online pharmacy provider option and independent telehealth.
Additionally, it will make a telemedicine connection with a healthcare professional to evaluate their symptoms and eligibility for treatment within two hours for a minimal expense.
Furthermore, if required, patients can get a prescription for an approved oral Covid-19 medication for same-day pickup at a nearby pharmacy. The platform will eventually be expanded to include home delivery of medicines.
The COVID-19 Care Journey is now accessible in 36 states and Washington, D.C., and will be made available nationwide beginning the week of 6 February.
Ada, co-founder and CEO Daniel Nathrath said: “Tackling conditions such as Covid-19 swiftly and effectively is imperative to improving people’s wellbeing and livelihoods, as well as alleviating the immense pressure it puts on global health systems and economies.
“The Ada COVID-19 Care Journey aims to significantly reduce the time from testing to treatment for users, and we firmly believe that it has the potential to improve health outcomes for millions.”
Users can access the COVID-19 Care Journey through Ada’s dedicated website by conducting self-screening or following a symptom assessment in the Ada app, which indicates the disease as a likely condition.
Pfizer Global and US antiviral franchise lead JoyL Silva said: “Connected digital health initiatives are a key step in lower cost, faster, more equitable and more convenient access to healthcare. Our collaboration with Ada is designed to educate patients on high-risk factors for severe COVID-19 and introduce choices for people to access a provider and learn about treatment options.
“We are excited to be a part of this COVID-19 Care Journey and for its potential to help reach some of the most vulnerable patients across the United States.”